The role of xerostomia in burning mouth syndrome: a case-control study / O papel da xerostomia na sindrome da ardencia bucal: estudo caso controle
Arq. neuropsiquiatr
;
72(2): 91-98, 02/2014. tab, graf
Article
in English
| LILACS
| ID: lil-702554
ABSTRACT
Objective:
To assess the efficacy of anti-xerostomic topical medication (urea 10%) in patients with burning mouth syndrome (BMS).Method:
Thirty-eight subjects diagnosed with BMS according to the International Association for the Study of Pain guidelines were randomized to either placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben, and 10% glycerol in distilled water qsp 100 g) or treatment (urea 10%) to be applied to the oral cavity 3-4 times per day for 3 months. The patients were evaluated before and after treatment with the following instruments the EDOF-HC protocol (Orofacial Pain Clinic – Hospital das Clínicas), a xerostomia questionnaire, and quantitative sensory testing.Results:
There were no differences in salivary flow or gustative, olfactory, or sensory thresholds (P>0.05). Fifteen (60%) patients reported improvement with the treatments (P=0.336).Conclusion:
In conclusion, there were no differences between groups, and both exhibited an association between reported improvement and salivation. .RESUMO
Objetivo:
Avaliar a eficácia do uso de medicação tópica anti xerostomica (ureia 10%) em pacientes com síndrome de ardência bucal.Método:
Trinta e oito sujeitos diagnosticados com síndrome de ardência bucal de acordo com os critérios da Associação Internacional para Estudo da Dor foram randomizados para grupo placebo (5% de carboximetilcelulose de sódio, 0,15% de metilparabeno e 10% de glicerol em água destilada qsp 100g) ou grupo tratamento (ureia 10%) para ser aplicada na cavidade oral 3-4 vezes ao dia, durante três meses. Os pacientes foram avaliados antes e depois do tratamento protocolo EDOF-HC, questionário de xerostomia, testes sensitivos quantitativos.Resultados:
Não houve diferenças no fluxo salivar, limiares gustativos, olfativos e somestésicos (Mann-Whitney P>0,05). Quinze (60%) dos pacientes tiveram melhora com o tratamento (P=0,336, oneway ANOVA ).Conclusão:
Em conclusão não houve diferenças entre os grupos, ambos apresentaram uma associação entre melhora e salivação. .
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Urea
/
Xerostomia
/
Burning Mouth Syndrome
/
Analgesics, Non-Narcotic
/
Amitriptyline
Type of study:
Controlled clinical trial
/
Practice guideline
/
Observational study
/
Qualitative research
/
Risk factors
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
English
Journal:
Arq. neuropsiquiatr
Journal subject:
Neurology
/
Psychiatry
Year:
2014
Type:
Article
/
Project document
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade de Sao Paulo/BR
Similar
MEDLINE
...
LILACS
LIS